Neurocrine Biosciences Inc (NBIX)

Debt-to-capital ratio

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Long-term debt US$ in thousands — — — — — — — 169,500 0 0 169,000 377,700 335,100 330,700 326,300 322,000 317,900 425,000 419,500 414,100
Total stockholders’ equity US$ in thousands 2,589,700 2,718,900 2,509,200 2,386,100 2,232,000 2,002,100 1,853,000 1,684,500 1,707,800 1,544,600 1,423,400 1,391,100 1,374,000 1,346,000 1,279,200 1,205,600 1,126,200 804,300 831,200 700,300
Debt-to-capital ratio 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.09 0.00 0.00 0.11 0.21 0.20 0.20 0.20 0.21 0.22 0.35 0.34 0.37

December 31, 2024 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $2,589,700K)
= 0.00

The debt-to-capital ratio for Neurocrine Biosciences Inc has shown a significant downward trend over the past few years. As of December 31, 2024, the debt-to-capital ratio stands at 0.00, indicating that the company has no debt relative to its capital structure. This suggests that Neurocrine Biosciences has a conservative approach to financing its operations, relying more on equity financing rather than debt.

The decreasing trend in the debt-to-capital ratio over the years may reflect the company's efforts to reduce debt levels and strengthen its financial position. A lower debt-to-capital ratio generally indicates lower financial risk and greater financial stability for the company.

It is worth noting that having a debt-to-capital ratio of 0.00 does not necessarily mean that the company has no debt at all, as there might be some debt that is not captured in the calculation. However, the consistent 0.00 ratio over multiple periods indicates a relatively strong capital base compared to debt levels for Neurocrine Biosciences Inc.